Background {#Sec1}
==========

Guidelines on managing NVP-related adverse reactions {#Sec2}
----------------------------------------------------

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral medicines for the treatment of people infected with the human immunodeficiency virus (HIV) \[[@CR1]\]. The use of NVP-containing antiretroviral therapy (ART) has proven its worth as evidenced by the significant reductions in HIV-associated morbidity and mortality in regions where NVP-containing ART regimens were preferred \[[@CR2]\]. Nevertheless, NVP is known to cause adverse reactions (AR) on the skin and in the liver, which necessitate NVP's substitution if the reaction is severe or persists without resolution. Namibia's ART guidelines have consistently recommended the continuation of NVP, with observation, for the patient who experienced a grade I AR to NVP; the substitution of NVP with efavirenz for the patient who experienced a grade II AR; and the substitution of NVP with lopinavir/ritonavir (LPV/r) a protease inhibitor, for the patient who experienced grade III or IV ARs to NVP \[[@CR3]\] (See Table [1](#Tab1){ref-type="table"}).Table 1Namibia ART guidelines 2008, 2010, and 2014 on the Use of NVP and response to NVP-related adverse reactionsYear of GuidelinesCD4 count threshold for ART initiationPreferred ART regimenResponse following NVP-related adverse drug reaction (skin and liver)Recommended Second Line ARTPre-2008\<200cells/mm^3^D4T/3TC/NVP• Grade I observe, add some medicineTDF/3TC/LPV/r2008\<200cells/mm^3^AZT/3TC/NVPTDF/3TC/LPV/r2010≤350cells/mm^3^TDF/3TC/NVP• Grade II, replace NVP with EFVTDF/3TC/AZT/LPV/r• Grade III or IV, replace NVP with LPV/r2014≤500cells/mm^3^TDF/FTC/EFVLeft blank -- focus is placed on NVPAZT/FTC/LPV/r*D4T* Stavudine, *3TC* Lamivudine, *NVP* Nevirapine, *AZT* Zidovudine, *TDF* Tenofovir, *FTC* Emtricitabine, *EFV* Efavirenz, *LPV/r* Lopinavir/ritonavir

NVP-use recommended in ART naïve patients with high baseline CD4 cell counts {#Sec3}
----------------------------------------------------------------------------

NVP's prescribing information has for long recommended the avoidance of NVP in women and men with CD4 cell counts ≥ 250 and ≥400 cells/mm^3^ respectively. This safety measure was devised to reduce incidences of serious NVP-related AR on the skin and in the liver \[[@CR4]\]. Over the years, this safety measure was countered by a number of studies that have suggested that the incidence of NVP-related skin and liver AR in patients with high baseline CD4 cell counts -- ≥250 in females and ≥400 in males -- was not different from the incidence in patients with low baseline CD4 counts \[[@CR5]--[@CR12]\]. On the contrary, results from other similar studies maintained that the incidence of NVP-related skin and liver reactions was higher in patients starting NVP-based antiretroviral therapy (ART) at high baseline CD4 cell counts than in patients with low baseline CD4 counts \[[@CR13]--[@CR17]\]. Nevertheless, based on the then available evidence, the World Health Organisation (WHO) recommended the use of NVP-based ART in all patients with a CD4 cell count \<350 cells/mm^3^, including ART naïve females with a CD4 count \>250 but \<350cells/mm^3^ \[[@CR1]\]. In 2010, Namibia's Ministry of Health and Social Services (MoHSS) launched the Third Edition of the National Guidelines for ART, which emulated the WHO's ART guidelines in regards to the threshold CD4 count for initiating ART, and the preferred first line ART regimen, namely: tenofovir (TDF)/lamivudine (3TC) and NVP \[[@CR3]\]. Also, the guidelines recommended close monitoring of liver function and careful examination of skin and mucosal surfaces of patients during the first weeks of NVP-containing ART, especially for females with baseline CD4 counts greater than 250 cells/mm^3^ \[[@CR1], [@CR3]\]. (See Table [1](#Tab1){ref-type="table"}).

Detection of a significant increase in spontaneous reports of grade III and IV AR related to NVP: Signal detection {#Sec4}
------------------------------------------------------------------------------------------------------------------

About one year after the launch of Namibia's 2010 ART Guidelines the Therapeutics Information and Pharmacovigilance Centre (TIPC) carried out an analysis of the spontaneous AR reports. They compared the numbers and proportions of reports that were received from 2008 to 2010 -- that is before the 2010 ART guidelines -- with those that were received in 2011. The results showed a statistically significant increase in the reports of grade III and IV skin and liver reactions associated with NVP in 2011 compared with previous years (2008 to 2010) (*p* \< 0.0001). In contrast to this result, there was no change in the frequency of grade I and II reactions (*P* = 0.16) between the periods. TIPC concluded that the increase in frequency of NVP-related grade III and IV reactions was a signal of the increase in grade III and IV ARs associated with NVP \[[@CR18]\]. (See [Appendix 1](#Sec19){ref-type="sec"}: Table 5 for the results obtained during the signal detection phase of NVP-safety analysis, and [Appendix 2](#Sec20){ref-type="sec"}: Table 6 for the statistical significance of the results). The skin- and liver- related reactions reports for NVP were compared with EFV-related reaction reports. This comparison showed that there was no change in the EFV-related reports, proving that the increase in reaction reports was unique to NVP. Similarly, the number of reports for EFV and NVP were compared with the number of reports for other medicines. This comparison showed that the increase in reports in 2011 was a finding unique to NVP. The within medicine comparison (NVP before and NVP after the 2010 ART guidelines) and the between medicine comparisons were done using Reaction Ratio, and Proportional Reaction Ratio \[[@CR18]\]. (See [Appendix 3](#Sec21){ref-type="sec"}: Tables 7 and 8 for the comparisons between NVP related reaction reports before and after the 2010 ART guidelines, and for the comparison between other medicines and EFV, and NVP).

The need to confirm or dispel the NVP-safety signal: TIPC's mandate {#Sec5}
-------------------------------------------------------------------

Since the above findings were based on spontaneous reports that were sent to the pharmacovigilance center voluntarily no conclusions could be drawn about the frequency of grade III and IV reactions at clinic level. (See the legend of [Appendix 1](#Sec19){ref-type="sec"}: Table 5 for the actual reactions that were reported to TIPC.) The clinical importance \[[@CR19]\] of these reactions required the TIPC to carry out further analysis to generate evidence that would confirm or dispel the NVP safety signal.

In this paper we present the objectives methods, and results that were generated from the research activity that TIPC undertook to assess the NVP-safety signal. Also, we present the discussion of the findings, and highlight the associated policy changes that followed. We believe that this paper demonstrates that local pharmacovigilance activities, based on locally generated data are beneficial to local populations.

Objective {#Sec6}
=========

The objective of this assessment was to find out if the increase in spontaneous reports of grade III and IV reactions associated with NVP was a true reflection of an increase in grade III and IV reaction events at clinic level. We set out to estimate the incidence of substitution of NVP with a protease inhibitor (PI) during the period 2008 to 2011 and to determine if any increase detected was statistically significant.

Methods {#Sec7}
=======

Automated antiretroviral (ARV) medicine dispensing records for adult patients who were newly started on ART during the period January 1 2008 to November 30, 2011 were accessed from the National Antiretroviral Dispensing Database. The proportion of records that showed the substitution of NVP with a PI per quarter from January 2008 to November 2011 was calculated. Comparisons between and within gender were made using the Odds Ratio, Proportional Reporting Ratio, and Reporting Ratio, with the confidence interval and statistical significance set at 95 % and a p-value of \<0.05, respectively. (In this paper the substitution of NVP with a PI is frequently referred to as a NVP-to-PI substitution. The PI that was mainly used is LPV/r).

Ethical approval {#Sec8}
----------------

Patient consent was not sought because antiretroviral data was sourced from existing databases and clinical records without requiring additional information directly from patients. ART dispensing data was captured in the national database housed in the Ministry of Health and Social Services' Division of Pharmaceutical Services. Only TIPC staff members mandated by the MoHSS to implement medicines safety analyses were involved in the medical record abstraction process and in the epidemiological study considered to be a public health activity. Confidentiality was observed.

Results {#Sec9}
=======

Frequency {#Sec10}
---------

A total of 84 741 patients were initiated on ART from January 2008 to November 2011. Of these, 67 794 were initiated on a NVP-containing regimen. For 290 patients NVP was substituted with a PI (Fig. [1](#Fig1){ref-type="fig"}). The period from the start of ART to when NVP was replaced with a PI, and the number of patients in whom this happened is shown in Table [2](#Tab2){ref-type="table"}. The mean (and median) ages of the males and females were 41 (39) years and 36 (35) years, respectively.Fig. 1Selection of records with a NVP-to-PI substitutionTable 2Number of patients with a NVP-to-PI substitutionTime after starting ART (number of weeks)Number of NVP to PI substitutionsTotal200820092010201123721224416231242668243270846112647101471224122491025143563171632341218012472014341222111252400235Total254893124290Throughout the period that was assessed, the majority of NVP-to-PI substitutions took place within the first12 weeks of ART. Higher numbers of substitutions are observed in 2010 and even higher in 2011 than the two previous years

The Frequency of ART initiation {#Sec11}
-------------------------------

From the first quarter of 2008 to the third quarter of 2010 the average number of HIV- positive patients who were initiated on ART per quarter was 3 437 (Fig. [2](#Fig2){ref-type="fig"}). There was an increase in this number in the third quarter of 2010.Fig. 2The figure shows that in the last quarter of 2010, the number of NVP-to-PI substitutions exceeded those in the previous quarters, as did the number of patients newly started on ART (*n* = 5 352). These substitutions peaked in the first quarter of 2011, but dropped in the subsequent two quarters. In the last quarter of 2011, the number of patients started on ART reverted to the earlier total level (*n* = 3 025)

Proportion of patients with a NVP- to-PI substitutions {#Sec12}
------------------------------------------------------

From the second quarter of 2010, the frequency of NVP-to-PI substitutions rose constantly to a peak of 0.95 % in the second quarter of 2011. In the third quarter of 2011 the frequency dropped slightly to 0.70 %, and then sharply by the last quarter of 2011 to 0.20 % (Fig. [2](#Fig2){ref-type="fig"}).

Increase in the Use of TDF-based first line HAART {#Sec13}
-------------------------------------------------

An increase in the use of TDF-based HAART is observed in the last two quarters of 2010 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3A major increase in TDF as a part of the nucleoside backbone in first line antiretroviral therapy is observed in the last quarter of 2010. Although a reduction is observed in the consequent months, the use of TDF remained high compared to what it was in the earlier quarters

Trends in the NVP-to-PI Substitutions according to gender {#Sec14}
---------------------------------------------------------

The majority of NVP-to-PI substitutions occurred in females (72.7 %, *n* = 211).

Females {#Sec15}
-------

The proportion of NVP-to-PI substitutions peaked in the third quarter of 2010. The odds of getting a NVP-to-PI substitution in the third quarter of 2010 and afterwards was 2.4 times the odds of getting the same substitution in the earlier period (January 2008 to June 2010) (95 % CI 1.8--3.1; *p* \< 0.0001) (Table [3](#Tab3){ref-type="table"}).Table 3Comparison of Frequencies of NVP-to-PI Substitutions before and after July 2010: Results According to GenderNo. Started ART before Q3 2010No. changed from NVP to PINo. Started ART in and after Q3 2010No. changed from NVP to PIOdds Ratio (CI)*P*-valueFemales21 0347416 5401372.4 (1.8--3.1)\<0.0001Males13 012289 987512.4 (1.4--3.8)0.0002

Males {#Sec16}
-----

The NVP-to-PI substitutions in males fluctuated through the entire period with a spike in the second quarter of 2011 (Fig. [4](#Fig4){ref-type="fig"}). The odds of needing a NVP-to-PI substitution from the third quarter of 2010 and afterwards was 2.4 times the odds of getting the same substitution in the earlier period (January 2008 to June 2010) (95 % CI 1.4--3.8; *p* = 0.0002) (Table [3](#Tab3){ref-type="table"}).Fig. 4Shows an increase in NVP-to-PI substitution in the third quarter of 2010, which was maintained for the consequent three quarters. We observed a decline in NVP-to-PI substitutions in the third quarter of 2011

Before and after July 2010, the odds of needing a NVP-to-PI substitution in females was 1.6 times that for males (*P* \<0.05) (Table [4](#Tab4){ref-type="table"}).Table 4Number of NVP-to-PI Substitutions for females vs. males before and after the Launch of the 2010 ART GuidelinesPeriodMalesFemalesOdds Ratio (CI)*P*-valueNo. started on ARTNo changed from NVP to PINo. started on ARTNo. changed from NVP to PIJuly 2010 and after9,9875116,5401371.6 (1.2--2 .2)0.003Before July 201013,0122821,034741.6 (1.1--2.5)0.03

Discussion {#Sec17}
==========

The assumption that the substitution of NVP with a PI (mainly LPV/r) within 24 weeks of ART was made due to grade III or IV ARs, was substantiated by the following. First: NVP-related reactions of liver and skin are known to occur mainly within the first few weeks of ART, but they may also occur as late as 18 weeks and more \[[@CR4], [@CR16]\]. Second: Namibia's 2010 ART guidelines recommended that when a grade III or IV AR -- such as Steven-Johnson's Syndrome, Toxic Epidermal Necrolysis, and very high alanine transferase levels in plasma (hepatotoxicity) -- occurs, NVP should be substituted with LPV/r \[[@CR3]\]. Third: The replacement of NVP with LPV/r, without any alteration in the nucleoside backbone, within six months of ART was not judged to be treatment failure. Namibia's 2008 ART guidelines recommended adherence-counselling for patients with poor virologic response before, at, or after six months of ART \[[@CR3]\]. Therefore, TDF/3TC/LPV/r was considered to be a first line regimen.

During the period before the publication of Namibia's 2010 ART guidelines, TDF had been prescribed as part of the nucleoside backbone of first line ART only when zidovudine or stavudine were contraindicated \[[@CR20]\]. Immediately after the publication of these guidelines, there was a substantial increase in the dispensing of TDF/3TC/NVP, the new preferred first line regimen. This immediate increase in the dispensing of TDF/3TC/NVP was not surprising, because the coordination between the Division of Pharmaceutical Services (DPS) and the Directorate of Special Programs (DSP) allowed the publication of the guidelines only when the medicines were available at the Central Medical Stores. \[The DPS is in charge of the supply chain management of all pharmaceuticals for the Ministry of Health; and DSP is responsible for HIV care and treatment.\] Therefore, compliance to the ART guidelines on issues such as the choice of first line ART regimen was facilitated, on the big part, by availability of the regimen, but also by the training of health care workers (HCW), who work in health facilities that provide ART.

The publication of the 2010 ART guidelines was followed by the increase in the number of patients who were newly initiated on ART. The previous guidelines recommended that one was eligible for ART when one's CD4 count was \<200cells/mm^3^. During that period (2008--Early 2010), an average of 3,414 patients were initiated on first line ART per quarter (Range = 613). The 2010 ART guidelines recommended that one was eligible for ART when one's CD4 count was ≤350cells/mm^3^. After the 2010 ART guidelines were published, in the fourth quarter of 2010, a total of 5352 were initiated on ART. In the next quarter -- Jan-Mar 2011 -- almost 6000 patients were initiated on ART. The average number of patients newly started on ART for these two quarters -- 5,676 -- was greater than the average of the previous period by 60 %. A TIPC report concerning the safety of NVP, showed that HIV infected patients were initiated on ART when their baseline CD4 cell count was \>200cells/mm^3^ \["Personal Communications" -- Dr. Assegid Mengistu\]. Also, the analysis of NVP-related reaction reports showed that the majority of those who had the baseline CD4 cell counts recorded on the report (*n* = 55), were females (*n* = 48). Of these, 60 % had baseline CD4 cell counts \>250 cells/mm^3^. It is likely that the increase in the number of patients initiated on ART was a result of initiating NVP-containing ART in patients with a CD4 cell count \>200cells/mm^3^.

The increase in NVP-to-PI substitutions that was observed from the third quarter of 2010 to the third quarter of 2011 started with the use of TDF/3TC/NVP (Fig. [4](#Fig4){ref-type="fig"}). Since the new guidelines had lifted the prohibition of the use of NVP in females with baseline CD4 counts \>250cells/mm^3^, plus the fact that female patients were indeed given NVP-containing first line ART with CD4 counts \>250cells/mm^3^, we believed that the increase in NVP-to-PI substitutions was associated with the high baseline CD4 cell count in females. However, the number of patients for whom NVP was replaced with a PI was low, despite the statistical significance. We supposed that the few NVP-to-PI substitutions were because only a handful of female patients had a baseline CD4 cell count \>250cells/mm^3^ at the start of TDF/3TC/NVP. This supposition borrowed evidence from the prospective study that TIPC carried out to assess the safety of first line ART, which showed that indeed many patients were initiated on ART with a CD4 cell count \<250cells/mm^3^ \["Personal Communication" -- Dr. Assegid Mengistu\]. The reduction in the number of patients newly started on ART, coupled with the decline in the number of NVP-to-PI substitutions, may be due to reversion of HCW to the previous ART guidelines in regards to the safety of NVP.

Our findings were limited by the following reasons. First: We eliminated all records of patients who were changed from NVP to, and remained on EFV. This impacts on the results, because it is possible that NVP was substituted with EFV following ARs of any severity level -- grades 1 to 4 -- without recurrence or escalation of the reaction. For a sustained, unrelenting grade I reaction, or grade II reaction, the substitution of NVP with EFV is appropriate \[[@CR20]\]. However, for grade III or IV reactions, the change to EFV is not recommended \[[@CR21]\]. On the other hand, it was worth eliminating these since a change from NVP to EFV may have been implemented because of the management of tuberculosis, but this was not verifiable, by virtue of the data source that was employed. Second: we eliminated records of patients who were changed from NVP to LPV/r through EFV. We eliminated these, because we did not know whether the change to LPV/r was due to a reaction associated with EFV or it was the worsening of NVP's reaction. Therefore, the elimination of records may have downplayed the proportion of NVP related reactions. The increase in the number of NVP-to-PI substitutions could be used to explain the increase in NVP-related skin and liver AR reports that were shown in the analysis of NVP-related AR reports \[[@CR18]\]. Another limitation to this study was the lack of baseline CD4 count data. This data would have solidified our argument. Nevertheless, the argument stood the test as the new ART guidelines reverted back to the former safety measures: to avoid NVP in females with baseline CD4 counts above 250cells/mm^3^.

Conclusion {#Sec18}
==========

The incidence of NVP-related reactions of grade III and IV increased with the implementation of Namibia's 2010 ART Guidelines, which recommended the use of NVP in females with baseline (pre-ART) CD4 cell counts \>250 cells/mm^3^. Therefore, the NVP safety signal was indeed a true signal. We proposed that initiating NVP-containing ART in women with high baseline CD4 counts, that is \>250cells/mm^3^, was a key factor in the incidence of NVP-related grade III and IV reactions. The decision to halt the initiation of NVP-containing ART in all pregnant females in Namibia with high baseline CD4 cell counts was a significant intervention made by the MoHSS through the use of pharmacovigilance information from TIPC. We published an article on this NVP's safety concern, in which we recommended a review on the use of NVP in Namibia. Namibia's newest ART guidelines -- 2014 guidelines -- recommend the avoidance of NVP-containing ART in females and males with a baseline CD4 count \>250 and 400 cells/mm^3^, respectively. We cannot claim that our findings were the sole reason for the change in guidelines, but we can say that they were contributory. National pharmacovigilance activities can be protective to patients, thus there is need for governments to strengthen local pharmacovigilance practice.

Appendix 1 {#Sec19}
==========

Table 5Number of adverse reactions related to antiretrovirals, nevirapine, and other medicines in 2011 and in the Previous Years (2008 - 2010)Adverse Reaction Reports20112008--2010 (previous years)RR*n* = 481*n* = 593Adverse reaction related to antiretroviral medicines389 (80.9 %)482 (81.3 %)1Total NVP reactions (related to skin and liver)Adverse reactions attributed to NVP208 (43.2 %)99 (16.7 %)2.6NVP skin reactionsAll skin reactions150 (31.2 %)70 (11.8 %)2.6Severe109 (22.7 %)33 (5.6 %)4.1Mild/moderate41 (8.5 %)37 (6.2 %)1.4NVP-liver reactionsAll liver reactions58 (12.1 %)29 (4.9 %)2.5Severe41 (8.5 %)13 (2.2 %)3.9Mild/moderate13 (2.7 %)14 (2.4 %)1.1Unknown grade4 (0.83 %)2 (0.34 %)-Other antiretroviral medicine reactionsAdverse reactions attributed to other medicines273 (56.8 %)494 (83.3 %)0.7The severe skin reaction reports in 2011 included: Stevens-Johnson Syndrome (*n* = 54), Toxic Epidermal Necrolysis (*n* = 3), Erythema Multiforme Major (*n* = 1), Skin reactions with conjunctivitis and oral lesions (51). In the Previous Years the severe reactions included the same reactions but much fewer reports. Note: The adverse reaction reports that never provided any form of description of the type of reaction -- e.g., skin rash, were regarded as mild or moderate. The severe liver reaction reports in 2011 included: High alanine aminotransferase i.e., above 5× the upper limit of normal (many were far above this), hyperbilirubinaemia, and some were reported as severe hepatotoxicity. Reports that never provided description of the liver reaction were considered to be mild or moderate

Appendix 2 {#Sec20}
==========

Table 6Statistical analysis of the difference between proportions of NVP-related adverse reactions of skin and liver% (95 % CI)Adverse reaction type2011Previous years*P*-valueARVRelated reactions (all)80.9 % (77.4 %--84.4 %)81.3 % (78.1 %--84.5 %)0.87NVP-relatedSkin and liver43.2 % (38.7 %--47.7 %)16.7 % (13.7 %--19.7 %)\<0.0001Skin (all)31.2 % (27.0 %--35.5 %)11.8 % (9.2 %--14.4 %)\<0.0001Skin: severe22.7 % (18.9 %--26.5 %)5.6 % (3.7 %%--7.5 %)\<0.0001Skin: mild/moderate8.5 % (6.0 %--11.0 %)6.2 % (4.2 %--8.2 %)0.16Liver (all)12.1 % (9.2 %--15.0 %)4.9 % (3.1 %--6.7 %)\<0.0001Liver: severe8.5 % (6.0 %--11.0 %)2.2 % (1.0 %--3.4 %)\<0.0001Liver: mild/moderate2.7 % (1.0 %--4.4 %)2.4 % (1.2 %--3.6 %)0.73Other medicinesSkin and liver5.0 % (3.0 %--7.0 %)9.9 % (7.5 %--12.3 %)0.002NVP-related reactions forFemales29.5 % (25.4 %--33.6 %)12.5 % (9.8 %--15.2 %)\<0.0001Females: severe21.6 % (17.9 %--25.3 %)5.6 % (3.7 %--7.5 %)\<0.0001Females: skin-severe17.3 % (13.9 %--20.7 %)4.0 % (2.4 %--5.6 %)\<0.0001Females: liver-severe4.3 % (2.5 %--6.1 %)1.5 % (0.5 %--2.5 %)0.0072Males13.7 % (10.6 %--16.8 %)3.9 % (2.3 %--5.5 %)\<0.0001Males: severe9.6 % (6.9 %--12.3 %)2.2 % (1.0 %--3.4 %)\<0.0001Males: skin-severe5.4 % (3.4 %--7.4 %)1.5 % (0.5 %--2.5 %)0.0007Males: liver-severe4.2 % (2.4 %--6.0 %)0.7 % (0.0 %--1.4 %)0.0003The results in the above table show that there was an increase in proportion of reports of severe reactions to NVP, on the skin and liver. The results also show that there was no increase in the mild and moderate reactions

Appendix 3: Comparison of NVP-related reaction reports with reports of adverse effects for EFV and other Medicines {#Sec21}
==================================================================================================================

Comparison of proportions of NVP- with EFV- related reactions {#Sec22}
-------------------------------------------------------------

The Reaction Ratio (RR) for NVP was greater than that for EFV for both skin and liver associated reactions.

Table 7RRs for NVP- and EFV- related adverse reaction reportsCategory of reactionNVPEFVSkin2.61.9Liver2.50.4

Comparison of proportions of NVP- and EFV- related reactions with other medicines {#Sec23}
---------------------------------------------------------------------------------

The Proportional Reporting Ratio (PRR) values for NVP were greater than those for EFV.

Table 8PRR for NVP- and EFV- related adverse reaction reportsCategory of reactionPRR for NVPPRR for EFV2011Previous years2011Previous yearsSkin3.81.50.060.06Liver9.72.20.030.17
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